Crossmark

Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong’s perspective

Crossref DOI link: https://doi.org/10.1038/s41391-019-0161-2

Published Online: 2019-07-04

Published Print: 2020-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chiang, Chi Leung

So, Tsz Him

Lam, Tai Chung

Choi, Horace C. W.
License Information

Text and Data Mining valid from 2019-07-04

Version of Record valid from 2019-07-04
More Information

Article History

Received: 27 March 2019

Revised: 6 May 2019

Accepted: 9 May 2019

First Online: 4 July 2019

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below